Vivos exchanges $2.86M Streeterville debt for 11.45M shares, 52% dilution

Vivos Therapeutics, Inc.

Exchanged $2,861,270 of Streeterville Note principal for 11,445,080 common shares (avg $0.25/share) on Sept 2, 2026.
Shares represent ~52% of pre-exchange outstanding (22,164,313) and ~34% of post-exchange (33,609,393).
Following exchanges, Streeterville Note balance reduced to $3.7 million; no cash proceeds received.
Exchanges done via 12 agreements; shares unregistered, issued under Section 3(a)(9).
Amendment corrects original 8-K report date to Sept 2, 2026; transactions consummated that date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.